Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656329 · ClinicalTrials.gov registry record · Phase 3
International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device
A Phase 3 study, sponsored by GE Healthcare.
- Terminated
- Registry status
- Phase 3
- Development phase
- 395
- Enrollment target
NCT02656329: Clinical Trial Phase 3 study, sponsored by GE Healthcare.
NCT02656329 is a Phase 3 study that was terminated before completion, run by GE Healthcare. The registered enrollment target is 395 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02656329, a Phase 3 study, was terminated before completion, sponsored by GE Healthcare.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 395 participants
- Enrollment target
Study Summary
This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure participants with 25%\<=left ventricular ejection fraction (LVEF)\<=35%, and in particular, for identifying participants who are at low risk for sudden cardiac death and who would not benefit, or may suffer harm, from implantation of an ICD device.
Primary Outcome
All-cause mortality included all reported deaths of participants during the study due to any cause. Percentage of participants who died due to any cause were reported.
Interventions
- DEVICE Implantable Cardioverter Defibrillator
- DRUG Iobenguane I -123 Injection
- DRUG Thyroid blocking
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2015-12-30 |
| Est. Completion | 2018-05-04 |
| Phase | Phase 3 |
Why NCT02656329 stopped before completion
NCT02656329 is an interventional study that assigns participants to a tested intervention. The registered 395 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 3 interventions - of which Implantable Cardioverter Defibrillator is the first listed.
NCT02656329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02656329 about?
NCT02656329 is a clinical study titled "International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device". This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure parti...
What is the current status of trial NCT02656329?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 395 participants. The study started on 2015-12-30. Estimated completion is 2018-05-04.
What interventions are being tested in trial NCT02656329?
The interventions under investigation include: Implantable Cardioverter Defibrillator (DEVICE), Iobenguane I -123 Injection (DRUG), Thyroid blocking (DRUG).
Who is sponsoring clinical trial NCT02656329?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02656329's enrollment target sits among peer trials
395 965th of 2000 higher than 1,034 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI